Viewing Study NCT00121316



Ignite Creation Date: 2024-05-05 @ 11:45 AM
Last Modification Date: 2024-10-26 @ 9:12 AM
Study NCT ID: NCT00121316
Status: COMPLETED
Last Update Posted: 2008-01-15
First Post: 2005-07-13

Brief Title: Safety and Efficacy of Pimecrolimus Cream 1 in Mild to Moderate Head and Neck Atopic Dermatitis AD Patients
Sponsor: Novartis
Organization: Novartis

Study Overview

Official Title: Safety and Efficacy of Pimecrolimus Cream 1 in Mild to Moderate Head and Neck Atopic Dermatitis AD of Patients Intolerant to or Dependant on Topical Corticosteroids
Status: COMPLETED
Status Verified Date: 2008-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is not being conducted in the United States

Patients who are intolerant of topical corticosteroids TCS have either experienced an adverse event resulting from the use of TCS or require unacceptable levels of exposure to TCS in order to control their AD This is of particular concern for patients with recurrent flares on delicate skin areas such as the head and neck

The purpose of this study is to investigate whether pimecrolimus cream 1 a non-steroidal anti-inflammatory drug is efficacious in treating mild to moderate head and neck AD in patients who are intolerant of or dependent on topical corticosteroids
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None